Fig. 4
From: MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis
MOG-CAR Tregs engineered from MS patient blood are functionally active in vitro. (A) Percentage of naïve Tregs (CD25hi CD127lo CD45RA+) among the CD4 cells of healthy donors and RRMS patients. (B) Fold expansion of healthy donors (grey) and RRMS patients (red) Tregs between day 0 to day 11 of the culture. (C) Percentage of transduction of the MOG-CAR with the lentivirus vector (at 1.107UI/ml) in Tregs from healthy donors and RRMS patients. (D) Percentage of FOXP3 expression, FOXP3 TSDR hypomethylation and Helios expression on Tregs from healthy donors and RRMS patients. (E) Activation of MOG-CAR Tregs from healthy and RRMS patients analyzed using activation marker CD69 expression at cell surface of Tregs. Tregs were incubated 24 h with media, anti-CD3/CD28 beads or coated MOG (3 µg/ml). (F) Suppression of human CD4 polyclonally stimulated responder T cell (Tconv) proliferation by human MOG-CAR Tregs from healthy donors or RRMS patients in co-culture. Human Tregs were pre-stimulated with culture media (no activation), anti-CD3/CD28 beads, or MOG coated protein (3 µg/ml). Two-way ANOVA with Tukey’s multiple comparisons test was performed. *p < 0.05, **p < 0.01